Active Filter(s):
Details:
Indicated for depression, LY03005 is a serotonin-norepinephrine-dopamine triple reuptake inhibitor developed by Luye Pharma’s New Chemical and Therapeutic Entities R&D platform.
Lead Product(s): Ansofaxine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: LY03005
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2020